First filing for Astellas' SGLT2 inhibitor contender ipragliflozin, in Japan
This article was originally published in Scrip
Astellas has landed the first blow in what will be a highly competitive market for sodium-glucose co-transporter 2 (SGLT2) inhibitors in Japan, with an approval filing for ipragliflozin (ASP1941) for type 2 diabetes.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.